Details research and clinical trials in the use of nucleoside analogs against chronic lymphocytic leukemia, hairy cell leukemia, and non-Hodgkin's lymphomas. Explains aspects including cellular pharmacology and mechanisms of action, strategies for combination therapy, induction of apoptosis, pharmacokinetics of purine nucleoside analogs, development of various drugs, optimal dose, nucleoside analogs as radiosensitizing agents, and toxicities associated with purine analog therapy. Reports on clinical trials with the agents in leukemia, lymphomas, other hematologic malignancies, and nonmalignant disorders. For cancer researchers and clinicians. Annotation c. by Book News, Inc., Portland, Or.
Offering the most current and complete coverage of nucleoside analog activity in oncology and hematology, this single-source volume includes topics from pharmacology to previously unpublished clinical findings on the pivotal role of fludarabine, cladribine, and pentostatin in the management of diseases, such as chronic lymphocytic and hairy cell leukemia, non-Hodgkin's lymphoma, membranous nephropathy, and rheumatoid and psoriatic arthritis.
Arvustused
" this volume is the first overview summarising the state of the art of purine analogs. The editors were able to get excellent papers togetherrecommend[ ed] to all haemato-oncologists who treat patients with purine analogs. "-Annals of Oncology
Nucleoside Analogs: Cellular Pharmacology, Mechanisms of Action, and
Strategies for Combination Therapy, William Plunkett and Varsha Gandhi
Induction of Apoptosis by Nucleoside Analogs, Peng Huang and Susan Wright
Pharmacokinetics of Purine Nucleoside Analogs, Jan Liliemark and Gunnar
Juliusson
Clinical Development of 2'-Deoxycoformycin, Bruce D. Cheson and Michael R.
Grever
Clinical Development of Fludarabine, Axel-R. Hanauske and Daniel D. Von Hoff
Development of 2-Chlorodeoxyadenosine (2-CdA) as a Chemotherapeutic and
Immunosuppressive Drug, Ernest Beutler, Dennis Carson, Robert McMillan, and
Robert Longmire
Defining the Optimal Dose Schedule of Purine Analogs and Assessment of
Response, Jorge E. Cortes and Susan M. O'Brien
Clinical Trials of the Purine Analogs in Chronic Lymphocytic Leukemia,
Michael J. Keating
Treatment of Hairy Cell Leukemia with Nucleoside Analogs, Alan Saven and
Lawrence D. Piro
Clinical Trials with Nucleoside Analogs in Lymphomas, Wolfgang Hiddemann and
Christiane Pott-Hoeck
Clinical Trials with Nucleoside Analogs in Other Hematologic Malignancies,
Jorge E. Cortes, Hagop Kantarjian, Susan M. O'Brien, and Michael J. Keating
Nucleoside Analogs as Radiosensitizing Agents, Vincent Grégoire and Walter N.
Hittelman
2-Chlorodeoxyadenosine in Nonmalignant Disorders, Ernest Beutler, Dennis
Carson, J. C. Sipe, J. S. Romine, Robert McMillan, Z. M. Younossi, V. D.
Rodgers, James A. Koziol, and J. Zyroff
Fludarabine in Nonmalignant Disorders, Ioannis O. Tassiulas, John C. Davis,
Jr., Barri J. Fessler, Nobuaki Hama, Thomas A. Fleisher, Howard A. Austin
III, and Dimitrios T. Boumpas
Toxicities Associated with Purine Analog Therapy, Bruce D. Cheson
Bruce D. Cheson (Edited by) , Michael J. Keating (Edited by) , William Plunkett (Edited by)
Lisainfo e-raamatute kohta